Literature DB >> 17039228

Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice.

M Ninomiya1, A Abe, A Katsumi, J Xu, M Ito, F Arai, T Suda, M Ito, H Kiyoi, T Kinoshita, T Naoe.   

Abstract

The cellular components of the hematopoietic stem cell niche have been gradually identified. However, the niche for malignant hematopoiesis remains to be elucidated. Here, using human leukemia cells, which could be transplanted to immunodeficient mice, we studied the in vivo homing, proliferation and survival sites by immunohistopathology, compared with the corresponding sites for cord blood CD34(+) (CBCD34(+)) cells. The human leukemia cells initially localized on the surface of osteoblasts in the epiphysial region, and expanded to the inner vascular and diaphysial regions within 4 weeks. The percentage of CD34(+) leukemia cells in the bone marrow was transiently increased up to 50%. In vivo 5-bromo-2'-deoxyuridine labeling revealed that the epiphysis was the most active site for leukemia cell proliferation. CBCD34(+) cells showed the similar pattern of homing and proliferation to leukemia cells. After high-dose administration of cytosine-1-beta-D-arabinofuranoside, residual leukemia cells were localized in the perivascular endothelium as well as in contact with the trabecular endosteum. These findings suggest that xenotransplantation into immunodeficient mice provides a useful model to study the leukemia niche.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039228     DOI: 10.1038/sj.leu.2404432

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  41 in total

1.  Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.

Authors:  Benjamin J Frisch; John M Ashton; Lianping Xing; Michael W Becker; Craig T Jordan; Laura M Calvi
Journal:  Blood       Date:  2011-09-28       Impact factor: 22.113

Review 2.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

Review 3.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

Review 4.  Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice.

Authors:  Yoriko Saito; Leonard D Shultz; Fumihiko Ishikawa
Journal:  Trends Immunol       Date:  2020-07-03       Impact factor: 16.687

5.  Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma.

Authors:  K Shimada; S Shimada; K Sugimoto; M Nakatochi; M Suguro; A Hirakawa; T D Hocking; I Takeuchi; T Tokunaga; Y Takagi; A Sakamoto; T Aoki; T Naoe; S Nakamura; F Hayakawa; M Seto; A Tomita; H Kiyoi
Journal:  Leukemia       Date:  2016-03-22       Impact factor: 11.528

6.  Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.

Authors:  M Benezra; E Phillips; D Tilki; B-S Ding; J Butler; K Dobrenkov; B Siim; D Chaplin; S Rafii; S Rabbany; M S Bradbury
Journal:  Leukemia       Date:  2012-02-20       Impact factor: 11.528

7.  Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice.

Authors:  Leonard D Shultz; Yoriko Saito; Yuho Najima; Satoshi Tanaka; Toshiki Ochi; Mariko Tomizawa; Takehiko Doi; Akiko Sone; Nahoko Suzuki; Hiroshi Fujiwara; Masaki Yasukawa; Fumihiko Ishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

8.  Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells.

Authors:  Chen Glait-Santar; Ronan Desmond; Xingmin Feng; Taha Bat; Jichun Chen; Elisabeth Heuston; Benjamin Mizukawa; James C Mulloy; David M Bodine; Andre Larochelle; Cynthia E Dunbar
Journal:  Stem Cells       Date:  2015-10-05       Impact factor: 6.277

9.  A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.

Authors:  Daniel J Goff; Angela Court Recart; Anil Sadarangani; Hye-Jung Chun; Christian L Barrett; Maryla Krajewska; Heather Leu; Janine Low-Marchelli; Wenxue Ma; Alice Y Shih; Jun Wei; Dayong Zhai; Ifat Geron; Minya Pu; Lei Bao; Ryan Chuang; Larisa Balaian; Jason Gotlib; Mark Minden; Giovanni Martinelli; Jessica Rusert; Kim-Hien Dao; Kamran Shazand; Peggy Wentworth; Kristen M Smith; Christina A M Jamieson; Sheldon R Morris; Karen Messer; Lawrence S B Goldstein; Thomas J Hudson; Marco Marra; Kelly A Frazer; Maurizio Pellecchia; John C Reed; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

10.  GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.

Authors:  Yusuke Shiozawa; Elisabeth A Pedersen; Russell S Taichman
Journal:  Exp Hematol       Date:  2009-11-14       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.